Key Highlights

  • Shares were down 11.68% to USD 4.99 in pre-market trading on November 3, 2026.
  • No company announcement dated November 2 or November 3, 2026 was identified.
  • Nasdaq staff determined on October 8, 2026 to delist the stock for failing the USD 2.5 million Equity rule.
  • The Cortigent Merger remained pending final regulatory approval as of October 30, 2026.
  • Vivani would own about 77.98% of the combined company, excluding the financing.

What moved ClearOne shares in pre-market trading (down USD 0.6599, 11.68%)

ClearOne (NASDAQ:CLRO) was down 11.68% to USD 4.99 in pre-market trading on November 3, 2026. The implied prior close from Monday, November 2, 2026 is about USD 5.65 (calculated).

No company announcement dated November 2 or November 3, 2026 was identified. The pullback follows a stretch of extreme swings, with a market commentary reporting about 83.1 million shares traded on October 26, 2026 against a public float of roughly 714,000.

The Cortigent merger and financing

Under an agreement announced July 2, 2026, Cortigent, Inc., a Subsidiary of Vivani Medical (NASDAQ:VANI), would become a Wholly Owned Subsidiary of ClearOne. On October 30, 2026 Vivani said closing remained pending final regulatory approval after an earlier expectation of an October close.

A regulatory filing says Vivani would own about 77.98% of the combined company, with existing ClearOne holders at about 16.69%. Closing is conditioned on a financing of USD 10.0 million to USD 15.0 million in units of one share and one warrant, which builds new dilution into the structure.

Business background and recent results

ClearOne historically made audio conferencing and collaboration products. It sold those Assets to Biamp Systems for USD 3.0 million gross, closing on October 24, 2025, and said it would remain a public company. Cortigent is a pre-revenue neurostimulation company whose Orion cortical visual prosthesis is investigational.

For the June 2026 quarter, market data shows a net loss of about USD 914,000 and cash of about USD 75,000. The auditors have expressed substantial doubt about the company's ability to continue as a going concern.

Listing and Balance Sheet risks

Nasdaq staff determined on October 8, 2026 to delist the shares because ClearOne did not meet the USD 2.5 million stockholders' equity requirement or complete its May 22, 2026 compliance plan. The company said it would request a hearing by October 15, 2026, which pauses any suspension while the panel considers a new plan.

Its majority holder has provided a Loan of up to USD 1 million due December 30, 2026. At under USD 5 with about 2.68 million shares outstanding, this Penny Stock carries heavy volatility, Liquidity and dilution risk.

What to watch next

Key markers are any announcement of regulatory clearance, pricing of the financing, the Nasdaq hearing outcome and any reverse split ratio. The merger filing places the outside date around late December 2026 (calculated from the filing terms).

Without new disclosure, trading may remain driven by the tiny float rather than company news.